Advertisement

Headache as an Adverse Reaction to Medication

  • Anna Ferrari
  • Peer Carsten Tfelt-Hansen
Reference work entry

Abstract

Headache is one of the most common adverse reactions induced by several drugs belonging to a wide variety of therapeutic classes, particularly cardiovascular drugs. It is probably more frequent than reported. In fact, identifying adverse reaction headache can be arduous, since headache is a non-pathognomonic symptom and a primary disorder widespread in the general population. Adverse reaction headache has no typical characteristics and can simulate a primary headache, be associated with symptoms of neurotoxicity, and be a sign of important conditions, such as pseudotumor cerebri or aseptic meningitis. Among subjects at risk are mainly the elderly. The International Classification of Headache Disorders (ICHD-II) (2004) includes headache – adverse drug reaction – in secondary forms, principally in Chap. 8, “Headaches attributed to drugs or their withdrawal,” codes 8.1, 8.3, and 8.4. Among these, the most known and easily recognized is certainly nitric oxide donor–induced headache, for example, induced by glyceryl trinitrate. Headache-provoking properties of nitric oxide donors have provided a human model of primary headache to study its pathophysiology and treatment.

The stronger evidence for the diagnosis of headache as adverse reaction, i.e., a negative event with a causal link with a drug, is disappearance with suspension, and the recurrence of headache with the resumption of the drug. Temporal association between exposure to a drug and headache may instead occur by pure coincidence. In most cases, adverse reaction headache does not endanger the patient’s life, it is of type A and dose-related, it occurs early in treatment (then tolerance develops), and its outcome is favorable. It can however also be very disturbing, and lead to discontinuation of the treatment. If not recognized, adverse reaction headache increases the suffering, worries the patient and the physician, and may lead to requests for investigations and the prescription of more drugs when the solution is the opposite (to reduce or stop drugs).

Keywords

Adverse Reaction Adverse Drug Reaction Migraine Attack Intracranial Hypertension Migraine Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Ang ER, Zimmerman JC, Malkin E (2002) Pseudotumor cerebri secondary to minocycline intake. J Am Board Fam Pract 15:229–233PubMedGoogle Scholar
  2. Aronson JK (2009) Medication errors: what they are, how they happen, and how to avoid them. QJM 102:513–521PubMedCrossRefGoogle Scholar
  3. Asch RH, Greenblatt RB (1977) The use of impeded androgen-danazol- in the management of benign breast disorders. Am J Obstet Gynecol 127:130PubMedGoogle Scholar
  4. Asmark H, Lundberg PO, Olsson S (1989) Drug-related headache. Headache 29:441–444CrossRefGoogle Scholar
  5. Bank J (2001) Migraine with aura after administration of sublingual nitroglycerin tablets. Headache 41:84–87PubMedCrossRefGoogle Scholar
  6. Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc 287:622–627CrossRefGoogle Scholar
  7. Bendtsen L, Jensen R (2009) Tension-type headache. Neurol Clin 27:525–535PubMedCrossRefGoogle Scholar
  8. Bhatt A, Farooq MU, Majid A, Kassab M (2009) Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol 5:163–169PubMedCrossRefGoogle Scholar
  9. Biswas PN, Wilton LV, Shakir SW (2002) The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens 16:795–803PubMedCrossRefGoogle Scholar
  10. Brache V, Faundes A, Alvarez F, Cochon L (2002) Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 65:63–74PubMedCrossRefGoogle Scholar
  11. Bruning PF (1992) Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 28:1404–1407CrossRefGoogle Scholar
  12. Claessens AA, Heerdink ER, van Eijk JT, Lamers CB, Leufkens HG (2002) Determinants of headache in lansoprazole users in the Netherlands: results from a nested case-control study. Drug Saf 25:287–295PubMedCrossRefGoogle Scholar
  13. Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD (2009) Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 29:1021–1027PubMedCrossRefGoogle Scholar
  14. Dinn RB, Wall M (2006) Tadalafil associated with typical migraine aura without headache. Cephalalgia 26:1344–1346PubMedCrossRefGoogle Scholar
  15. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259PubMedCrossRefGoogle Scholar
  16. Ekbom K (1968) Nitrolglycerin as a provocative agent in cluster headache. Arch Neurol 19:487–493PubMedGoogle Scholar
  17. Evans RW (2006) Sildenafil can trigger cluster headaches. Headache 46:173–174PubMedCrossRefGoogle Scholar
  18. Evans RW, Kruuse C (2004) Phosphodiesterase-5 inhibitors and migraine. Headache 44:925–926PubMedCrossRefGoogle Scholar
  19. Ferrari A (2006) Headache: one of the most common and troublesome adverse reactions to drugs. Curr Drug Saf 1:43–58PubMedCrossRefGoogle Scholar
  20. Ferrari U, Empl M, Kim KS, Sostak P, Forderreuther S, Starube A (2005) Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms. Headache 45:211–214PubMedCrossRefGoogle Scholar
  21. Ferrari A, Spaccapelo L, Gallesi D, Sternieri E (2009) Focus on headache as an adverse reaction to drugs. J Headache Pain 10:235–239PubMedCrossRefGoogle Scholar
  22. Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, Pepe G, Colusso AM, Pacilli L, Pilotto A (2008) Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 31:545–556PubMedCrossRefGoogle Scholar
  23. Friedman DI, De ver Dye T (2009) Migraine and the environment. Headache 49:941–952PubMedCrossRefGoogle Scholar
  24. Ganguly S (2005) All-trans retinoic acid related headache in patients with acute promyelocytic leukemia: prophylaxis and treatment with acetazolamide. Leu Res 29:721CrossRefGoogle Scholar
  25. Gaul C, Eismann R, Schmidt T, May A, Leinisch E, Wieser T, Evers S, Henkel K, Franz G, Zierz S (2009) Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia 29:1069–1078PubMedCrossRefGoogle Scholar
  26. Gautier S, Bachelet H, Bordet R, Caron J (2003) The cost of adverse drug reactions. Expert Opin Pharmacother 4:319–326PubMedCrossRefGoogle Scholar
  27. Giezen TJ, Mantel-Teeuwisse LHG (2009) Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf 32:811–817PubMedCrossRefGoogle Scholar
  28. Glasser SP, Ripa S, Garland WT, Weiss R, Nademanee K, Singh S, Bittar N (1995) Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina. J Clin Pharmacol 35:780–784PubMedGoogle Scholar
  29. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, European/Australasian Stroke Prevention in Reversible Ischaemia Trial Study Group (2009) Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 80:437–439PubMedCrossRefGoogle Scholar
  30. Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385–396PubMedCrossRefGoogle Scholar
  31. Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):1–160CrossRefGoogle Scholar
  32. Iversen HK, Olesen J, Tfelt-Hansen P (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38:17–24PubMedCrossRefGoogle Scholar
  33. Ivey KJ, Denssesten L (1969) Pseudotumor cerebri associated with corticosteroid therapy in an adult. J Am Med Assoc 208:1698–1700CrossRefGoogle Scholar
  34. Jacobs JH, Grayson MF (1968) Trial of an anti-inflammatory agent (indomethacin) in low back pain with and without radicular involvement. Br Med J 3:158–160PubMedCrossRefGoogle Scholar
  35. Jensen R, Stovner LJ (2008) Epidemiology and comorbidity of headache. Lancet Neurol 7:354–361PubMedCrossRefGoogle Scholar
  36. Kaufman DW, Shapiro S (2002) Epidemiological assessment of drug-induced disease. Lancet 356:1339–1343CrossRefGoogle Scholar
  37. Kepa L, Oczko-Grzesik B, Stolarz W, Sobala-Szczygiel B (2005) Drug-induced aseptic meningitis in suspected central nervous system infections. J Clin Neurosci 12:562–574PubMedCrossRefGoogle Scholar
  38. Khan RB (2002) Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol 17:857–858PubMedCrossRefGoogle Scholar
  39. Khromov A, Segal M, Nissinoff J, Fast A (2005) Migraines linked to interferon-beta treatment of multiple sclerosis. Am J Phys Med Rehabil 84:644–647PubMedCrossRefGoogle Scholar
  40. Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J (2004) Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia 24:547–553PubMedCrossRefGoogle Scholar
  41. Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J (2006) Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia 26:925–933PubMedCrossRefGoogle Scholar
  42. Lam GM, Edelson DP, Whelan CT (2010) Lamotrigine: an unusual etiology for aseptic meningitis. Neurologist 16:35–36PubMedCrossRefGoogle Scholar
  43. Larson EW (1993) Migraine with typical aura associated with fluoxetine therapy: case report. J Clin Psychiatry 54:235–236PubMedGoogle Scholar
  44. Lökk J (2009) Dipyridamole-associated headache in stroke patients–interindividual differences? Eur Neurol 62:109–113PubMedCrossRefGoogle Scholar
  45. Mangrella M, Motola G, Russo F, Mazzeo F, Giassa T, Falcone G, Rossi F, D’Alessio O, Rossi F (1998) Hospital intensive monitoring of adverse reactions of ACE inhibitors. Minerva Med 89:91–97PubMedGoogle Scholar
  46. Marley JE, Curram JB (1989) General practice data derived tolerability assessment of antihypertensive drugs. J Int Med Res 17:473–478PubMedGoogle Scholar
  47. Massiou U, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20:170–174PubMedCrossRefGoogle Scholar
  48. Massiou H, Launay JM, Levy C, El-Amrani M, Emperauger B, Bousser MG (2002) SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks. Neurology 58:1698–1699PubMedGoogle Scholar
  49. Michels KB (1999) Problems assessing non serious adverse drug reactions: antidepressant drug therapy and sexual dysfunction. Pharmacotherapy 19:424–429PubMedCrossRefGoogle Scholar
  50. Mishell DR, Shoupe D, Brenner PF, Lacarra M, Horenstein J, Lahteenmaki P, Spitz IM (1987) Termination of early gestation with the anti-progestin steroid RU 486: medium versus low dose. Contraception 35:307–321PubMedCrossRefGoogle Scholar
  51. Mochizuki K, Takahashi T, Kano M, Terajima K, Hori N (2002) Pseudotumor cerebri induced by minocycline therapy for acne vulgaris. Jpn J Ophthalmol 46:668–672PubMedCrossRefGoogle Scholar
  52. Moen J, Antonov K, Larsson CA, Lindblad U, Nilsson JL, Råstam L, Ring L (2009) Factors associated with multiple medication use in different age groups. Ann Pharmacother 43:1978–1985PubMedCrossRefGoogle Scholar
  53. Munera PA, Goldstein A (2001) Migraine and sertraline. J Am Acad Child Adolesc Psychiatry 40:1125–1126PubMedCrossRefGoogle Scholar
  54. Neidig JL, Koletar SL (2001) Safety reporting in clinical trials. J Am Med Assoc 285:2077–2078Google Scholar
  55. Neville BGR, Wilson J (1970) Benign intracranial hypertension following corticosteroid withdrawal in childhood. Br Med J 3:554–556PubMedCrossRefGoogle Scholar
  56. Noah BA (2009) Just a spoonful of sugar: drug safety for pediatric population. J Law Med Ethics 37:280–291PubMedCrossRefGoogle Scholar
  57. Olesen J, Thomsen LL, Lassen LH, Olesen IJ (1995) The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 15:94–100PubMedCrossRefGoogle Scholar
  58. Olin JL, Gugliotta JL (2003) Possible valacyclovir-related neurotoxicity and aseptic meningitis. Ann Pharmacother 37:1814–1817PubMedCrossRefGoogle Scholar
  59. Pollmann W, Erasmus LP, Feneberg W, Then Bergh F, Straube A (2002) Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 59:636–639PubMedGoogle Scholar
  60. Rehan HS, Chopra D, Kakkar AK (2009) Physician’s guide to pharmacovigilance: terminology and causality assessment. Eur J Intern Med 20:3–8PubMedCrossRefGoogle Scholar
  61. Reinisch VM, Sostak P, Straube A (2008) Headache in the elderly. MMW Fortschr Med 7:42–44Google Scholar
  62. Steiger MJ, Farrah T, Rolles K, Harvey P, Burroughs AK (1994) Cyclosporin associated headache. J Neurol Neurosurg Psychiatry 57:1258–1259PubMedCrossRefGoogle Scholar
  63. Tfelt-Hansen P, Steiner TJ (2007) Over-the-counter triptans for migraine: what are the implications? CNS Drugs 21:877–883PubMedCrossRefGoogle Scholar
  64. Tfelt-Hansen PC, Tfelt-Hansen J (2009) Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update. Headache 49:445–456PubMedCrossRefGoogle Scholar
  65. Tfelt-Hansen P, Daugaard D, Lassen LH, Iversen HK, Olesen J (2009) Prednisolone reduces nitric oxide-induced migraine. Eur J Neurol 16:1106–1111PubMedCrossRefGoogle Scholar
  66. Thadani U, Rodgers T (2006) Side effects of using nitrates to treat angina. Expert Opin Drug Saf 5:667–674PubMedCrossRefGoogle Scholar
  67. Toth CC, Burak K, Becker W (2005) Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution. Headache 45:245–246PubMedCrossRefGoogle Scholar
  68. Trontell A (2004) Expecting the unexpected - drug safety, pharmacovigilance, and prepared mind. N Engl J Med 351:1385–1387PubMedCrossRefGoogle Scholar
  69. Tvedskov JF, Iversen HK, Olesen J, Tfelt-Hansen P (2010) Nitroglycerin provocation in normal subjects is not a useful human migraine model? Cephalalgia 30:928–932PubMedCrossRefGoogle Scholar
  70. Vaughn C, Zhang L, Schiff D (2008) Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 10:86–91PubMedCrossRefGoogle Scholar
  71. Veehof LJ, Stewart RE, Meyboom-de Jong B et al (1999) Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol 55:533–536PubMedCrossRefGoogle Scholar
  72. Veneziano M, Framarino Dei Malatesta M, Bandiera AF, Fiorelli C, Galati M, Paolucci A (1995) Ondansetron-induced headache. Our experience in gynecological cancer. Eur J Gynaecol Oncol 16:203–207PubMedGoogle Scholar
  73. Visani G, Bontempo G, Manfroi S, Pazzaglia A, D’Alessandro R, Tura S (1996) All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Haematologica 81:152–154PubMedGoogle Scholar
  74. Wenmalm A, Carlsson F, Edlund A, Eriksson S, Kaijser L, Nowak J (1984) Central and peripheral haemodynamic effects of non-steroidal anti-inflammatory drugs in man. Arch Toxicol Suppl 7:350–359Google Scholar
  75. World Health Organization (1969) International drug monitoring: the role of the hospital. WHO Tech Rep Ser 425:5–25Google Scholar
  76. World Health Organization (1981) Cancer treatment: WHO recommendations for grading of acute and subacute toxicity. Cancer 47:207–214CrossRefGoogle Scholar

Copyright information

© Lifting The Burden 2011

Authors and Affiliations

  1. 1.Headache and Drug Abuse Inter-Dep. Research Centre, Division of Toxicology and Clinical PharmacologyUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Danish Headache Centre and Department of NeurologyGlostrup Hospital, University of CopenhagenGlostrupDenmark

Personalised recommendations